First ever 10-year outlook on chronic kidney disease highlights growing global health crisis

A new modelling analysis by UK pharma major AstraZeneca (LSE: AZN), IMPACT CKD, forecasts up to 16.5% of the population across eight countries will suffer from chronic kidney disease (CKD) by 2032, including a staggering rise of up to 59.3% in advanced-stage.

Presented at the 2024 ISN World Congress of Nephrology (WCN’24) in Buenos Aires, the study highlights an urgent and growing global health crisis with profound economic and environmental implications, said AstraZeneca.

IMPACT CKD is the first study to examine and forecast the vast, multi-dimensional impact of CKD over a 10-year time horizon across eight countries — the USA, Brazil, the UK, Spain, Germany, the Netherlands, China, and Australia.1